Related Experiment Video

Updated: May 26, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure

Atac Celik1, Semsettin Sahin, Fatih Koc

  • 1Department of Cardiology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey. dretaci@yahoo.com

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|December 31, 2011
PubMed

Insights

Cardiotrophin-1 (CT-1) is elevated in patients with diastolic heart failure (DHF). This cytokine is associated with NT-proBNP and elevated left ventricular filling pressures in DHF patients.

Area of Science:

  • Cardiology
  • Biochemistry
  • Medical Diagnostics

Background:

  • Cardiotrophin-1 (CT-1), an interleukin-6 family cytokine, is implicated in cardiovascular diseases.
  • Elevated CT-1 levels are observed in chronic heart failure.

Purpose of the Study:

  • To ascertain the association between plasma CT-1 and diastolic heart failure (DHF).
  • To investigate the relationship between CT-1 and echocardiographic parameters in DHF patients.

Main Methods:

  • A cohort of 57 DHF patients and 33 controls underwent echocardiography.
  • Blood samples were collected for CT-1 and NT-proBNP measurements.

Main Results:

  • CT-1 and NT-proBNP levels were significantly higher in DHF patients compared to controls.
  • Echocardiographic parameters indicative of elevated left ventricular filling pressures (e.g., E/Em, estimated PCWP) were significantly higher in DHF patients.
  • CT-1 showed positive correlations with NT-proBNP, mean E/Em, and estimated mean PCWP.

Conclusions:

  • Plasma CT-1 is elevated in patients diagnosed with DHF.
  • CT-1 levels are associated with NT-proBNP and estimated left ventricular filling pressures in DHF.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...